Filter news

Latest News


MedNous article: A surprise finding in the clinic

Every once in a while a discovery in the clinic exceeds researchers’ expectations. This is what happened in early February 2022 when Vicore, received early data from a Phase 2 study of our candidate product, C21, for idiopathic pulmonary fibrosis (IPF). Article published in MedNous (Vol 16, No 3, March… Read more


Patient insights to shape development of a dCBT for IPF patients

Survey analysis of the psychological aspects of living with IPF: 33 patients from 6 different countries. Results presented at the 2021 Pulmonary Fibrosis Foundation Summit. The poster session was presented by Jessica Shull, Director of Digital Therapeutics at Vicore Pharma. View poster in PDF… Read more


C21 shows promise against COVID-19 where other drugs have failed

By Carl-Johan Dalsgaard, CEO of Vicore Pharma The rapid development, and now distribution, of COVID-19 vaccines is welcome progress in the global fight against this pervasive and mutating virus. But we are far from being out of the woods yet. Recent data show that the Pfizer and Moderna vaccines are… Read more


Top line data on the ATTRACT study

It’s been a very busy few months at Vicore as we’ve continued to progress our studies into IPF and of course our COVID study, ATTRACT. As we now have some initial top line positive results from ATTRACT, we asked CMO Rohit Batta to talk about what the ATTRACT results might… Read more


Untangling the dualistic components of the RAS in PF the Yin and Yang

The Renin-Angiontensin System (RAS) has been studied for nearly 100 years, but there were some unexpected findings about it made only in the 1990s.  These findings have been the scientific foundation of much of our development work at Vicore. Vicore CMO, Rohit Batta, spoke about this journey during his presentation… Read more


Report on the ATTRACT study

Vicore CMO Rohit Batta has been making progress with our ATTRACT study, which will investigate a potential treatment for COVID-19.  Here’s Rohit’s report on what’s been happening: There’s an element of serendipity in how this study came about. As the details of how COVID-19 acts on the body became known,… Read more


Idiopathic Pulmonary Fibrosis: 5 Things to Know

There aren’t that many articles written to provide a practical guide to how a pulmonologist might approach a patient with suspected IPF – the real challenges. We found this article by Dr Aaron B. Holley; it is a gem, and certainly worth a read, especially when taking standard… Read more